RxDoctor Payments Data

Ashley Greenman, MD

Family Medicine · Lake Charles, LANPI 1962791699

Payments from drug & device makers

$7,764in general payments, 2019–2025

Across 469 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$652
  • Lilly USA, LLC$642
  • Pfizer$568
  • Takeda Pharmaceuticals U.S.A., Inc.$553
  • Novo Nordisk$440
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,746100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,764 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$90,801
Medicare patients
170
Services billed
2,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$109,258
MounjaroTirzepatide83$91,360
TrulicityDulaglutide52$63,797
FarxigaDapagliflozin Propanediol47$52,921
JardianceEmpagliflozin30$49,444
EliquisApixaban51$48,371
RexultiBrexpiprazole15$31,251
LinzessLinaclotide17$26,467
TrintellixVortioxetine Hydrobromide18$21,475
MyrbetriqMirabegron23$20,480
RybelsusSemaglutide11$19,882
XareltoRivaroxaban11$18,193
UbrelvyUbrogepant16$17,445
Janumet XrSitagliptin Phos/Metformin Hcl11$11,508
Repatha SureclickEvolocumab16$10,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$642$155,156135 claims
Novo NordiskOzempic, Rybelsus$440$129,14088 claims
AstraZenecaFarxiga$652$52,92147 claims
Boehringer IngelheimJardiance$113$49,44430 claims
PfizerEliquis$568$48,37151 claims
AbbVieLinzess, Ubrelvy, Synthroid$1,832$47,73665 claims
Otsuka America Pharmaceutical, Inc.Rexulti$151$31,25115 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$553$21,47518 claims
Astellas Pharma US IncMyrbetriq$272$20,48023 claims
Johnson & JohnsonXarelto$58$18,19311 claims
MerckJanumet Xr, Janumet$196$17,26322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →